Eli Lilly (LLY) says 7 out of 10 patients are choosing its obesity medicines through the government’s Medicare programme, according to a presentation

Eli Lilly (LLY) says 7 out of 10 patients are choosing its obesity medicines through the government’s Medicare programme, according to a presentation.

Company-sourced channel share data of this kind is a recurring feature of the obesity market contest, where Lilly and its principal competitor have traded claims on formulary access and patient preference through each new reimbursement channel. Government programme uptake is the tell that has mattered historically: once a large public payer opens coverage, volumes in this class have tended to scale quickly, and share within the channel becomes the competitive scoreboard rather than list pricing. The figure originates from the company itself and from a presentation rather than a filing, so it reflects the firm's chosen framing of the split against the competing franchise, and independent dispensing data has on past occasions told a different story to vendor presentations. The distinction worth drawing is between choice at the point of prescribing and persistence on therapy, since the revenue read-through depends on continuation rates rather than initial selection. The follow-ons are payer formulary updates, the competitor's channel share disclosures, and prescription trend data, which is where claims of this kind are confirmed or quietly dropped.